Pharma: Clinic Roundup
• A new retrospective subanalysis of the RE-LY trial suggested similar rates of periprocedural bleeding and thromboembolic complications in nonvalvular atrial fibrillation patients undergoing a surgical or invasive procedure treated with Pradaxa (dabigatran etexilate mesylate), from Boehringer Ingelheim GmbH, of Ingelheim, Germany, compared to warfarin.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST